Research Pulse — 2026-09-25 | Brown Biotech

# Research Pulse — 2026-09-25
_Generated 2026-09-25 07:30 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 9월 25일 (금요일) · Synergizing(시너지) Day**

9/25(시너지) → 9/24(확장) → 9/23(진전) → 9/22(집적화) → 9/21(정상화) → 9/20(실체화) → 9/19(제도화) → 9/18(산업화). Scaling(9/24)된 기술들이 **복수 기술 영역의 교차점에서 시너지가 발생하며, 구조 예측 × 분자 설계 × 약리활성 예측의 통합·단일세포 × 공간 전사체학의 융합·유전 치료 × 규제 과학의 협력 등 기술 간 결합으로 새로운 기능적 가치와 적용 가능성을 만들어내는 Synergizing(시너지) 단계로 이전하며, 기술이 단독 성과가 아닌 결합에 의해 새로운 가능성을 여는 날** — Kumar et al.으로 PASTE technology — serine integrases + prime editing + large DNA insertion + no double-strand break + permanent gene replacement(Current Pharmacogenomics 2026), Singh et al.으로 AlphaFold drug discovery 적용 hierarchical framework — task별 모델 성능 parsing + protein-ligand data 필요성(Current Opinion Structural Biology 2026), Ji et al.으로 CAPTAIN multimodal foundation model — scRNA + protein 382종 동시 측정 + cross-modality dependencies(Nature Communications 2026), Gao et al.으로 gastric cancer spatial atlas — Lymphocyte Aggregated Region + TLS + PD1+CD8 T proximity to CD70+LAMP3+ DC(Nature Communications 2026), Oo et al.으로 FDA gene therapy approvals 44개 comprehensive review — platform-aligned risk-based + plausible mechanism + CMC flexibility(Journal of Clinical Pharmacology 2026), DenAdel et al.으로 single-cell FM pretraining dataset scaling — 22.2M cells 400 models 6,400 experiments(Nature Methods 2026)이 동시에 진행된다.

Synergizing은 Scaling의 다음 단계다. 오늘 6개 전선은 확장된 기술들이 **복수 기술 영역의 교차점에서 시너지가 발생하며, 구조 × 설계 × 예측, 단일세포 × 공간, 유전 치료 × 규제 등 기술 간 결합으로 새로운 기능적 가치와 적용 가능성을 만들어내는 날**이다.

*출처: [Kumar PASTE Technology Current Pharmacogenomics 2026](https://consensus.app/papers/details/f67bc821c6de54adba196d75eba51aba/), [Singh AlphaFold Framework Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Ji CAPTAIN Multimodal Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Gao Gastric Cancer Spatial Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8812d6886aa485d9/), [Oo FDA Gene Therapy J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [DenAdel Single-Cell FM Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/)*

*#SynergizingDay #Kumar #PASTE #SerineIntegrase #PrimeEditing #LargeDNAInsertion #NoDSB #CurrentPharmacogenomics #Singh #AlphaFold #HierarchicalFramework #CurrentOpinion #StructuralBiology #Ji #CAPTAIN #Multimodal #NatureCommunications #382Proteins #Gao #GastricCancer #SpatialAtlas #LymphocyteAggregatedRegion #TLS #NatureCommunications #Oo #FDA #GeneTherapy #PlatformAligned #RiskBased #JClinicalPharmacology #DenAdel #NatureMethods #SingleCell #FoundationModel #Scaling #Synergizing #Integration #BiomedicalAI #DailyReport*

---

### Post 2: CRISPR & Gene Editing — PASTE Large DNA Insertion + PE Integrate + No DSB: Serine Integrase × Prime Editing Synergy

🪄 **[CRISPR/Gene Editing] Kumar et al.으로 PASTE technology — serine integrases + prime editing + large DNA insertion + no double-strand break + permanent gene replacement + natural gene regulation 유지(Current Pharmacogenomics 2026) + Kumar et al.으로 next-generation genome editing — CRISPR-Cas9 limitations 극복 체계적 분석 + PASTE technology hybrid: PASTE × PE Synergy(시너지) 확인**

CRISPR 유전자 편집 기술의** serine integrase × prime editing 결합 시너지 + large DNA insertion + no DSB**가 출처에서 확인된다[1].

**PASTE: Serine Integrase × Prime Editing + Large DNA Insertion + No DSB[1]**
Vikash Kumar et al.(Current Pharmacogenomics and Personalized Medicine 2026)의 review는 PASTE(Programmable Addition via Site-specific Targeting Elements) technology를 분석한다[1]. PASTE는 Cas9 nickase + reverse transcriptase + serine integrase hybrid system으로 작동한다. Large gene sequences의 정밀한 삽입이 가능하며, 이는 기존 DSB 기반 방식 대비 우월하다. No double-strand break 특성으로 불필요한 DSB 없이 gene replacement를 수행하며, indel risk가 최소화된다. Natural gene regulation이 유지되어 지속적 발현이 가능하다. Delivery options으로 LNPs, dual AAV systems, virus-like particles를 통해 transient하고 tissue-targeted delivery가 가능하다. Kumar et al.의 companion review는 CRISPR-Cas9 limitations克服을 위해 PASTE technology hybrid가 제시된다고 분석한다. PASTE technology로 serine integrase × prime editing synergy가 실현되며, 이는 large DNA insertion의 새로운 paradigm이다.

**9월 24일 확장(Tao AI-guided PE + Sakai PE-PRISM + Meng ContactSeek) vs 오늘의 차별점**: 9/24이 Tao Nature Biotechnology로 AI-guided reverse transcriptase redesign + 2.9-fold improvement를, Sakai Nature Biotechnology로 PE-PRISM 2,858 RNA motifs + 90%+ efficiency를, Meng Nature로 ContactSeek AlphaFold3 base editor specificity를 제시했다면, 오늘은 같은 CRISPR 분야에서 Kumar Current Pharmacogenomics PASTE으로 **serine integrase × prime editing hybrid + large DNA insertion + no DSB + natural gene regulation**을 제시한다. 확장(9/24) → PASTE × PE synergy + next-generation genome editing framework(9/25).

실무 함의: 유전 치료 개발팀에서 Kumar et al.의 PASTE technology를 분석하여 large gene insertion 전략을 수립해야 한다.

*출처: [Kumar PASTE Technology Current Pharmacogenomics 2026](https://consensus.app/papers/details/f67bc821c6de54adba196d75eba51aba/)*

*#CRISPR #PASTE #SerineIntegrase #PrimeEditing #LargeDNAInsertion #NoDSB #CurrentPharmacogenomics #Kumar #GeneReplacement #LNPs #AAV #VLP #NextGeneration #CRISPRCas9 #Limitations #Synergizing #LargeScale #Integration #BiomedicalAI*

---

### Post 3: AI 신약 — DrugCLIP Contrastive Learning × AlphaFold2 Synergy: 10M Times Faster + Genome-Wide Virtual Screening

💊 **[AI 신약] Singh et al.으로 AlphaFold drug discovery 적용 hierarchical framework — task별 모델 성능 parsing + protein-ligand data 필요성(Current Opinion in Structural Biology 2026) + Jia et al.으로 DrugCLIP — contrastive learning + AlphaFold2 structures + genome-wide virtual screening + 10 million times faster than docking + norepinephrine transporter 15% hit rate(Science 2026) + Lin et al.으로 Pharma AI 2026 Deals — Lilly·Novo Nordisk·AstraZeneca 실제 이행 확인(GEN Biotechnology 2026): 구조 AI × 분자 설계 시너지 확인**

AI-Driven Drug Discovery의** contrastive learning × AlphaFold2 structures synergy + genome-wide virtual screening**이 출처에서 확인된다[1][2][3].

**DrugCLIP: Contrastive Learning × AlphaFold2 + 10 Million Times Faster + Genome-Wide Screening[2]**
Yinjun Jia et al.(Science 2026)의 DrugCLIP은 contrastive learning framework로 genome-wide virtual screening을 실현한다[2]. DrugCLIP은 computational efficiency에서 revolutionary improvement를 달성했으며, docking 대비 **10 million times faster**이다. AlphaFold2 structures를 활용하여 structure-based drug discovery의 새로운 paradigm을 제시한다. Norepinephrine transporter에서 **15% hit rate**가 wet-lab validation으로 확인되었으며, thyroid hormone receptor 12에서는 **17.5% hit rate**가 holo structure 없이 AlphaFold2 predicted structure만으로 발견되었다. GenomeScreenDB로 **~10,000 human proteins × 500 million compounds**의 precomputed database를 제공한다. DrugCLIP contrastive learning × AlphaFold2 synergy가 실현되며, 이는 genome-wide virtual screening의 새로운 era이다.

**AlphaFold Drug Discovery 적용을 위한 Hierarchical Framework[1]**
Sukrit Singh et al.(Current Opinion in Structural Biology 2026)의 review는 AlphaFold drug discovery 적용을 위한 hierarchical framework를 분석한다[1]. Hierarchical framework는 task별 모델 성능 parsing을 가능하게 하며, data-centric approach로 experimental/physics-based datasets 필요성을 강조한다. Benchmark efforts를 통해 blind challenge로 모델 한계를 평가한다. Singh et al.의 framework는 AlphaFold drug discovery 적용을 위한 data-centric structural biology의 기반을 제시한다.

**Pharma AI 2026 Deals: Lilly·Novo Nordisk·AstraZeneca 실제 이행[3]**
Fay Lin(GEN Biotechnology 2026)의 기사는 2026년 빅파마 AI partnership 실제 이행을 분석한다[3]. Lilly, Novo Nordisk, AstraZeneca의 AI platform 거래가 실제 이행되었음이 확인된다. Pharma AI 2026 Deals의 실제 이행은 AI drug discovery 산업화를 뒷받침한다.

**9월 23일 진전(Lushington PE first-in-human + Yu PE efficiency + Pharma AI 2026 Deals) vs 오늘의 차별점**: 9/23이 Lushington Mol Ther로 PE first-in-human functional restoration을, Yu Advanced Science로 PE efficiency improvement를, Lin GEN Biotechnology로 Pharma AI 2026 Deals actual execution을 제시했다면, 오늘은 같은 AI drug discovery 분야에서 Jia Science DrugCLIP으로 **contrastive learning × AlphaFold2 synergy + 10M times faster + genome-wide screening**을, Singh Current Opinion Structural Biology으로 **AlphaFold drug discovery를 위한 hierarchical framework**를, Lin GEN Biotechnology으로 **Pharma AI 2026 Deals actual execution**을 동시에 제시한다. 진전(9/23) → contrastive learning × AF2 synergy + hierarchical framework + actual deals synergy(9/25).

실무 함의: 약리활성 연구팀에서 Jia et al.의 DrugCLIP framework를 분석하여 genome-wide virtual screening 전략을 수립해야 한다.

*출처: [Singh AlphaFold Framework Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Jia DrugCLIP Science 2026](https://consensus.app/papers/details/5acea8f3221b5acfa37184d1fe50da28/), [Lin Pharma AI 2026 Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/)*

*#AI #DrugDiscovery #DrugCLIP #ContrastiveLearning #AlphaFold2 #GenomeWide #VirtualScreening #10MillionTimes #Faster #Docking #Science #Jia #NorepinephrineTransporter #ThyroidHormone #HitRate #GenomeScreenDB #Singh #AlphaFold #CurrentOpinion #StructuralBiology #HierarchicalFramework #DataCentric #Lin #PharmaAI #2026Deals #GENBiotechnology #Lilly #NovoNordisk #AstraZeneca #Synergizing #Integration #BiomedicalAI*

---

### Post 4: 단백질 AI — AlphaFold3 Architecture Evolution + Pairformer Architecture + Future Prospects Synergy

🔬 **[단백질 AI] Chakraborty et al.으로 AlphaFold3 evolution + current status + future prospects — AF1→AF2→AF3 architectural evolution + Pairformer pairwise interactions + protein-ligand/protein-nucleic acid/protein-protein complexes +局限: protein dynamics/multiple conformational states(Frontiers in Artificial Intelligence 2026) + Singh et al.으로 AlphaFold drug discovery 적용 hierarchical framework(Current Opinion in Structural Biology 2026): 구조 예측 AI의 Architecture × Application 시너지 확인**

단백질 AI의** AlphaFold architecture evolution × application scope expansion synergy**가 출처에서 확인된다[1][2].

**AlphaFold3 Evolution, Current Status, and Future Prospects: Pairformer Architecture × Complex Prediction[1]**
Chakraborty et al.(Frontiers in Artificial Intelligence 2026)의 review는 AlphaFold의 architectural evolution과 미래 전망을 분석한다[1]. AlphaFold는 AF1(DNNs) → AF2(Evoformer, evolutionarily related sequences) → AF3(Pairformer, pairwise amino acid interactions)로 진화했다. Pairformer architecture는 pairwise interactions modeling으로 complex assembly 예측 향상을 가져온다. AF3는 protein-ligand, protein-nucleic acid, protein-protein complexes로 확장되었으며, AFDB accessibility로 translational research가 가속되었다. 다만 protein dynamics와 multiple conformational states 예측에는 한계가 있다. AlphaFold3 architecture evolution × complex prediction synergy가 실현되며, 이는 구조 예측 AI의 새로운 기준이다.

**AlphaFold Drug Discovery 적용을 위한 Hierarchical Framework[2]**
Singh et al.(Current Opinion in Structural Biology 2026)의 review는 AlphaFold drug discovery 적용을 위한 framework를 분석한다[2]. Hierarchical framework는 task별 모델 성능 parsing을 가능하게 하며, data-centric approach로 experimental/physics-based datasets 필요성을 강조한다. AlphaFold drug discovery 적용을 위한 hierarchical framework는 data-centric structural biology의 기반을 제시한다.

**9월 22일 집적화(Yin ESMFold/AF comprehensive review + Zhao DNA/RNA editing review) vs 오늘의 차별점**: 9/22이 Yin Frontiers Molecular Biosciences로 ESMFold/RoseTTAFold/AlphaFold comprehensive review를, Zhao Molecular Biomedicine로 DNA/RNA editing comprehensive review를 제시했다면, 오늘은 같은 구조 예측 분야에서 Chakraborty Frontiers AI AlphaFold3 evolution으로 **Pairformer × complex prediction synergy**을, Singh Current Opinion Structural Biology으로 **hierarchical framework × data-centric approach**를 동시에 제시한다. 집적화(9/22) → architecture × application synergy + data-centric framework synergy(9/25).

실무 함의: 구조생물학팀에서 Chakraborty et al.의 AlphaFold3 architecture evolution 결과를 분석하여 구조 예측 전략을 수립해야 한다.

*출처: [Chakraborty AlphaFold3 Frontiers Artificial Intelligence 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [Singh AlphaFold Framework Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)*

*#ProteinAI #AlphaFold #AlphaFold2 #AlphaFold3 #Chakraborty #FrontiersAI #Pairformer #Evoformer #Architecture #ProteinLigand #ProteinNucleicAcid #ProteinProtein #AFDB #StructuralBiology #Nobel #Singh #CurrentOpinion #StructuralBiology #HierarchicalFramework #DataCentric #Benchmark #ProteinDynamics #ConformationalStates #Synergizing #ArchitectureEvolution #Integration #BiomedicalAI*

---

### Post 5: Single-Cell Multi-Omics — CAPTAIN Multimodal × SCMBench Benchmark Synergy: 382 Proteins + scRNA + FM Integration

🔬 **[Single-Cell Multi-Omics] Ji et al.으로 CAPTAIN multimodal foundation model — scRNA + protein 382종 동시 측정 + cross-modality dependencies + COVID-19 immune severity dynamics(Nature Communications 2026) + Wang et al.으로 SCMBench — 23 methods benchmarking + 4 tasks + FMs fall short of DMs + lightweight adaptation strategy(Nature Communications 2026) + Cen et al.으로 single-cell/spatial omics comprehensive review — scRNA + spatial + multimodal + foundation model + biomedical applications(MedComm 2026): Multimodal × Benchmark 시너지 확인**

Single-Cell Multi-Omics의** multimodal foundation model × benchmark synergy**가 출처에서 확인된다[1][2][3].

**CAPTAIN: Multimodal FM with scRNA + 382 Proteins + Cross-Modality Dependencies[1]**
Boya Ji et al.(Nature Communications 2026)의 CAPTAIN은 co-assayed scRNA와 **382 proteins**으로 multimodal foundation model을 구현한다[1]. CAPTAIN은 **4M cells**에서 scRNA + protein measurement를 동시에 수행한다. Cross-modality dependencies modeling으로 transcriptomic-proteomic 통합 representation을 학습한다. Protein imputation and expansion에서 multimodal representation으로 향상된 단백질 예측을 달성하며, cell type annotation과 batch harmonization에서 superior performance를 보인다. COVID-19 severity dynamics에서 protein-driven intercellular dynamics와 immune interaction patterns이 severity와 연관됨을 발견했다. CAPTAIN multimodal × cross-modality synergy가 실현되며, 이는 protein-centric single-cell multi-omics의 새로운 paradigm이다.

**SCMBench: 23 Methods Benchmarking + FMs Fall Short of DMs + Lightweight Adaptation[2]**
Yixuan Wang et al.(Nature Communications 2026)의 SCMBench는 single-cell multi-omics integration의 comprehensive benchmarking을 수행한다[2]. **23 methods**을 4 tasks(integration accuracy, biomarker detection, trajectory inference, batch effect correction)로 평가한다. Foundation models이 domain-specific models보다 낮은 성능을 보이는 **FMs fall short of DMs** 현상이 확인된다. Lightweight adaptation strategy로 FM performance 향상이 가능하다. SCMBench benchmarking × FM limitation analysis synergy가 multi-omics integration의 현주소를 제시한다.

**Single-Cell and Spatial Omics Comprehensive Review[3]**
Xiaoping Cen et al.(MedComm 2026)의 review는 single-cell과 spatial omics의 포괄적 현황을 분석한다[3]. scRNA + spatial + multimodal 통합으로 high-resolution molecular profiling을 가능하게 한다. Foundation model 적용으로 generative AI + multimodal multiomics data를 활용하며, biomedical applications로 biomarker discovery, therapeutic target identification, precision medicine에 기여한다. Single-cell/spatial omics comprehensive review는 technology-application synergy를 제시한다.

**9월 21일 정상화(Ji CAPTAIN multimodal + Wang SCMBench lightweight adaptation) vs 오늘의 차별점**: 9/21이 Ji Nature Communications CAPTAIN으로 multimodal FM을, Wang Nature Communications SCMBench로 FM lightweight adaptation을 제시했다면, 오늘은 같은 multi-omics 분야에서 Ji Nature Communications CAPTAIN으로 **382 proteins × cross-modality dependencies × COVID-19 severity synergy**을 재확인하며, Wang SCMBench로 **23 methods × FMs fall short of DMs × lightweight adaptation**을, Cen MedComm으로 **scRNA + spatial + multimodal comprehensive review synergy**를 동시에 제시한다. 정상화(9/21) → multimodal × benchmark × comprehensive review synergy(9/25).

실무 함의: 단일세포 연구팀에서 Ji et al.의 CAPTAIN multimodal FM 결과를 분석하여 protein-centric multi-omics 전략을 수립해야 한다.

*출처: [Ji CAPTAIN Multimodal Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cen Single-Cell Spatial Omics MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)*

*#SingleCell #MultiOmics #CAPTAIN #Multimodal #FoundationModel #NatureCommunications #Ji #382Proteins #COVID19 #CrossModality #Wang #SCMBench #Benchmarking #DomainSpecific #FoundationModel #LightweightAdaptation #Cen #MedComm #Spatial #scRNA #PrecisionMedicine #Biomarker #Synergizing #Integration #BiomedicalAI*

---

### Post 6: FDA/규제 — FDA Platform-Aligned Risk-Based Initiatives × CGT 44 Approvals Synergy

🏥 **[FDA/규제] Oo et al.으로 FDA gene therapy approvals 1998–2025 comprehensive review — 44 approvals + platform-aligned risk-based initiatives + plausible mechanism framework + CMC flexibility initiative + advanced manufacturing technologies program(Journal of Clinical Pharmacology 2026) + Shahzad et al.으로 CGT 38개 approval analysis — 86.8% orphan designation + 92.1% expedited pathway + 73.7% single pivotal study + surrogate endpoints 44.7%(Clinical Pharmacology 2026) + Kunanayagam et al.으로 pediatric CGT pharmacology — dosing considerations + PK framework limitations + preclinical models reliance(Pediatric Research 2026): FDA platform-aligned regulatory science × CGT approval analysis 시너지 확인**

FDA/규제의** platform-aligned regulatory science × CGT comprehensive analysis synergy**가 출처에서 확인된다[1][2][3].

**FDA Gene Therapy Approvals 1998–2025: Platform-Aligned Risk-Based Initiatives[1]**
C. Oo et al.(Journal of Clinical Pharmacology 2026)의 review는 FDA gene therapy approvals의 진화와 미래 방향을 분석한다[1]. **44 approvals**가 May 2025까지 승인되었으며, 이는 gene therapy의 치료적 classe 확장을 보여준다. Platform-aligned risk-based initiatives는 개별 치료제 적응이 아닌 플랫폼 기반 규제 접근을 제시한다. Plausible mechanism framework는 gene therapy-specific regulatory framework이며, CMC flexibility initiative는 chemistry, manufacturing, controls 유연성을 제공한다. Advanced manufacturing technologies program은 gene therapy 제조 혁신을 지원하며, AI/ML-enabled analytics는 dose selection, safety evaluation, durability prediction을 지원한다. FDA platform-aligned regulatory science × gene therapy synergy가 regulatory innovation을 이끈다.

**CGT 38개 Approval Analysis: Orphan Designation + Expedited Pathway + Surrogate Endpoints[2]**
Mahnum Shahzad et al.(Clinical Pharmacology 2026)의 연구는 38개 CGT approval의 규제 분석을 수행한다[2]. **86.8% orphan designation**, **92.1% expedited pathway**, **73.7% single pivotal study**, **surrogate endpoints 44.7%**가 확인된다. Postmarketing requirements는 **73.4%**에서 필요하며, 이는 approval 후 추가 연구가 일반적임을 보여준다. CGT approval regulatory analysis는 expedited pathway × orphan designation synergy를 제시한다.

**Pediatric CGT Pharmacology: Dosing + PK Framework + Preclinical Models[3]**
S. Kunanayagam et al.(Pediatric Research 2026)의 review는 pediatric gene therapy의 임상약리학을 분석한다[3]. Dosing considerations으로 vector shedding과 biodistribution 특이성이 있으며, traditional PK principles는 적용되지 않는다. Cellular kinetics는 CAR-T, TIL expansion/persistence와 연관된다. Rare disease/pediatric population 대응을 위해 preclinical models에 의존한다. Pediatric CGT pharmacology는 dosing × PK × preclinical model synergy를 제시한다.

**9월 23일 진전(Litt FDA oncology AI 149 authorization + Hills FDA-EMA AI guiding principles) vs 오늘의 차별점**: 9/23이 Litt J Cancer Policy로 FDA oncology AI 149개 authorization을, Hills AI in Precision Oncology로 FDA-EMA 10 Guiding Principles를 제시했다면, 오늘은 같은 규제 분야에서 Oo J Clinical Pharmacology으로 **platform-aligned risk-based initiatives × 44 approvals × AI/ML analytics synergy**을, Shahzad Clinical Pharmacology으로 **orphan designation × expedited pathway × surrogate endpoints × 38 approvals analysis synergy**을, Kunanayagam Pediatric Research으로 **pediatric CGT dosing × PK × preclinical model synergy**를 동시에 제시한다. 진전(9/23) → platform-aligned regulatory science × comprehensive CGT analysis × pediatric pharmacology synergy(9/25).

실무 함의: 규제 팀에서 Oo et al.의 platform-aligned regulatory framework를 분석하여 gene therapy regulatory strategy를 수립해야 한다.

*출처: [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad CGT Approvals Clinical Pharmacology 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/), [Kunanayagam Pediatric CGT Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/)*

*#FDA #GeneTherapy #PlatformAligned #RiskBased #PlausibleMechanism #CMC #AdvancedManufacturing #JClinicalPharmacology #Oo #OrphanDesignation #ExpeditedPathway #SurrogateEndpoints #ClinicalPharmacology #Shahzad #Pediatric #Kunanayagam #PediatricResearch #Dosing #PK #Preclinical #CAR-T #TIL #Synergizing #RegulatoryScience #Integration #BiomedicalAI*

---

### Post 7: Spatial Transcriptomics/Cancer Atlas — Gastric Cancer LAR × SCLC LNM Atlas Synergy

🗺️ **[Spatial Transcriptomics/Cancer Atlas] Gao et al.으로 gastric cancer spatial atlas — Lymphocyte Aggregated Region + TLS + PD1+CD8 T cell proximity to CD70+LAMP3+ dendritic cells + immunotherapy biomarkers(Nature Communications 2026) + Zhang et al.으로 SCLC CosMx spatial — 75 patients 105 specimens 600,000 cells + vascular-immune crosstalk + pan-immune hotspot PIHs-1 survival predictor(Cell Reports Medicine 2026) + Li et al.으로 pan-cancer spatial transcriptomics — 12 cancer types 373 samples 56 LCPs 13 niches + Niche_4 poor prognosis + Niche_11 better survival(Cell Reports Medicine 2026): Spatial cancer atlas × immunotherapy biomarkers 시너지 확인**

Spatial Transcriptomics/Cancer Atlas의** Lymphocyte Aggregated Region × vascular-immune crosstalk × niche-specific biomarkers synergy**가 출처에서 확인된다[1][2][3].

**Gastric Cancer Spatial Atlas: Lymphocyte Aggregated Region + TLS + PD1+CD8 T Cell Proximity[1]**
Sen Gao et al.(Nature Communications 2026)의 연구는 gastric cancer spatial atlas로 lymphocyte aggregated region(LAR)을 동정한다[1]. LAR은 TLS(tertiary lymphoid structures)를 포함한다. PD1+CD27+ CD8 T cells는 CD70+LAMP3+ dendritic cells와 근접한 공간적 조직을 보인다. Group A는 activated lymphocytes, Group B는 resting lymphocytes로 상이한 공간적 분포를 보인다. LAR 기반 immunotherapy biomarkers가 개발 가능하며, 이는 gastric cancer LAR spatial atlas × immunotherapy biomarkers synergy를 제시한다.

**SCLC Spatial Transcriptomics: 600,000 Cells + Vascular-Immune Crosstalk + PIHs-1[2]**
Zicheng Zhang et al.(Cell Reports Medicine 2026)의 연구는 SCLC lymph node metastasis의 spatial cellular ecosystem을 분석한다[2]. **75 patients, 105 specimens, 600,000 cells** 규모의 세계 최대 SCLC spatial transcriptomics dataset을 구축했다. **3 LNM-enriched malignant subclusters**에서 distinct metabolic/angiogenic programs이 확인된다. Vascular-immune crosstalk에서 endothelial cells-mediated immune activation이 발견되며, **pan-immune hotspot PIHs-1**이 독립적 survival predictor로 기능한다. Functional perivascular niches에서 cytotoxic T cells와의 공간적 조직이 확인된다. SCLC LNM spatial atlas × vascular-immune crosstalk × PIHs-1 synergy가 metastatic spatial ecosystem을 설명한다.

**Pan-Cancer Spatial Transcriptomics: 12 Types 373 Samples 56 LCPs 13 Niches[3]**
Jiarong Li et al.(Cell Reports Medicine 2026)의 연구는 **12 cancer types, 373 samples**의 pan-cancer spatial transcriptomics를 수행한다[3]. **56 Local Cellular Programs(LCPs)**와 **13 recurrent niches**가 식별된다. **Niche_4**는 macrophages colocalized with tumor cells로 poor prognosis + immunotherapy resistance와 연관된다. **Niche_11**은 macrophages colocalized with immune cells로 better survival + treatment response와 연관된다. Pan-cancer spatial atlas × niche-specific biomarkers × immunotherapy response synergy가 tumor microenvironment architecture를 설명한다.

**9월 24일 확장(Yiu IN-DEPTH same-slide spatial multiomics + Zhang SCLC CosMx) vs 오늘의 차별점**: 9/24이 Yiu Cancer Discovery로 IN-DEPTH same-slide spatial multiomics protein-first workflow를, Zhang Cell Reports Medicine으로 SCLC CosMx 600,000 cells spatial을 제시했다면, 오늘은 같은 spatial transcriptomics 분야에서 Gao Nature Communications gastric cancer LAR으로 **Lymphocyte Aggregated Region × TLS × PD1+CD8 T proximity × immunotherapy biomarkers synergy**을, Zhang SCLC로 **vascular-immune crosstalk × PIHs-1 survival predictor**을 재확인하며, Li Cell Reports Medicine으로 **56 LCPs × 13 niches × Niche_4/Niche_11 prognostic biomarkers**를 동시에 제시한다. 확장(9/24) → LAR × vascular-immune crosstalk × niche-specific biomarkers × immunotherapy response synergy(9/25).

실무 함의: 종양면역학팀에서 Gao et al.의 gastric cancer LAR 결과를 분석하여 면역치료 biomarker 전략을 수립해야 한다.

*출처: [Gao Gastric Cancer Spatial Atlas Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8812d6886aa485d9/), [Zhang SCLC Spatial CosMx Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Li Pan-Cancer Spatial Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#SpatialTranscriptomics #CancerAtlas #GastricCancer #LymphocyteAggregatedRegion #LAR #TLS #NatureCommunications #Gao #PD1 #CD8 #CD70 #LAMP3 #DendriticCell #Zhang #SCLC #CosMx #600000Cells #VascularImmune #Crosstalk #PIHs1 #Survival #Li #PanCancer #56LCPs #13Niches #Niche4 #Niche11 #Prognostic #Biomarker #Immunotherapy #Resistance #Synergizing #SpatialEcosystem #Integration #BiomedicalAI*

---

### Post 8: 종합 — 9월 25일 시너지의 날의 핵심 교훈

🧬 **[종합] 9월 25일 시너지의 날: 확장된 기술들의 교차점에서 새로운 가능성을 여는 Synergizing의 날**

오늘(9월 25일)은 **시너지의 날(Synergizing Day)**이다. 확장된 기술들이 복수 기술 영역의 교차점에서 시너지가 발생하며 새로운 기능적 가치와 적용 가능성을 만들어내는 날이다.

**핵심 시너지 6가지**:

**CRISPR PASTE × Prime Editing Synergy**: Kumar et al.(Current Pharmacogenomics 2026)의 PASTE technology로 **serine integrase × prime editing 결합 + large DNA insertion + no DSB + natural gene regulation 유지**가 실현되었다[1].

**DrugCLIP Contrastive Learning × AlphaFold2 Synergy**: Jia et al.(Science 2026)의 DrugCLIP으로 **contrastive learning × AlphaFold2 structures + 10 million times faster than docking + genome-wide virtual screening**이 실현되었다[2].

**AlphaFold3 Architecture × Complex Prediction Synergy**: Chakraborty et al.(Frontiers AI 2026)의 AlphaFold3 review로 **AF1→AF2→AF3 architectural evolution + Pairformer pairwise interactions + protein-ligand/protein-nucleic acid/protein-protein complexes expansion**이 실현되었다[3].

**CAPTAIN Multimodal × SCMBench Benchmark Synergy**: Ji et al.(Nature Communications 2026)의 CAPTAIN으로 **scRNA + protein 382종 × cross-modality dependencies + COVID-19 severity immune dynamics**가 실현되었다. Wang et al.(Nature Communications 2026)의 SCMBench로 **23 methods × FMs fall short of DMs × lightweight adaptation**이 분석되었다[4].

**FDA Platform-Aligned × CGT Comprehensive Analysis Synergy**: Oo et al.(J Clinical Pharmacology 2026)의 FDA gene therapy approvals review로 **platform-aligned risk-based initiatives × plausible mechanism framework × CMC flexibility × advanced manufacturing × AI/ML analytics**가 제시되었다[5].

**Gastric Cancer LAR × SCLC LNM × Pan-Cancer Niches Spatial Synergy**: Gao et al.(Nature Communications 2026)의 gastric cancer spatial atlas로 **Lymphocyte Aggregated Region × TLS × PD1+CD8 T cell proximity × immunotherapy biomarkers**가 실현되었다. Zhang et al.(Cell Reports Medicine 2026)의 SCLC spatial atlas로 **600,000 cells × vascular-immune crosstalk × PIHs-1 survival predictor**가 실현되었다. Li et al.(Cell Reports Medicine 2026)의 pan-cancer analysis로 **56 LCPs × 13 niches × Niche_4 poor prognosis × Niche_11 better survival**가 제시되었다[6].

**시너지의 교훈**: Synergizing 단계에서 핵심은 **단독 성과가 아닌 결합에서 가치를 찾는 것**이다. PASTE × PE, contrastive learning × AlphaFold2, multimodal × benchmark, spatial atlas × immunotherapy biomarkers 등 기술 간 결합이 새로운 가능성을 연다. 다음 단계인 **Refining(정제) 단계**에서는 이 시너지에서 발견된 결합들의 효율성·정확성·재현성을 정밀하게 검증하고 체계화하는 것이 핵심이 될 것이다.

---

## Sources

1. [Kumar PASTE Technology Current Pharmacogenomics 2026](https://consensus.app/papers/details/f67bc821c6de54adba196d75eba51aba/)
2. [Singh AlphaFold Framework Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)
3. [Jia DrugCLIP Science 2026](https://consensus.app/papers/details/5acea8f3221b5acfa37184d1fe50da28/)
4. [Chakraborty AlphaFold3 Frontiers Artificial Intelligence 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/)
5. [Ji CAPTAIN Multimodal Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/)
6. [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/)
7. [Cen Single-Cell Spatial Omics MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)
8. [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)
9. [Shahzad CGT Approvals Clinical Pharmacology 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/)
10. [Kunanayagam Pediatric CGT Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/)
11. [Gao Gastric Cancer Spatial Atlas Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8812d6886aa485d9/)
12. [Zhang SCLC Spatial CosMx Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)
13. [Li Pan-Cancer Spatial Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)
14. [DenAdel Single-Cell FM Scaling Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/)
15. [Lin Pharma AI 2026 Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/)